Increase in dietary supplement use in the United States suggests a great need for clinicians to be aware of the range of their quality parameters.

Statutory limitations prevent the FDA from effectively regulating dietary supplements and have generated numerous calls for reform.

Illegal, fraudulent, adulterated, or improperly labeled products should be regarded as sources of possible clinical and ethical harm to patients.

Helping patients mitigate their risk of chronic disease is key, but dietary supplements are risky.

Defining typical appearance as a goal of health service provision is harmful and unnecessary for traits that are stigmatized but neither harmful nor distressing.

These key steps are ones health sector stakeholders should take to help patients and clinicians use pricing information to inform health decision making.

For dying patients and their loved ones to make informed decisions, physicians must share adequate information about prognoses, prospective benefits and harms of specific interventions, and costs.

Online tools intended to make health care purchasing resemble “consumerism” have had little effect on improving transparency for patients.

Negative health consequences from costly care are referred to as financial toxicity and should be included in informed consent discussions.

This article analyzes differences in prescription drug pricing transparency practices among 3 Organisation of Economic Co-operation and Development member nations.